Audentes Therapeutics Inc

Audentes Therapeutics — Investor Presentation (September 2017)

33 slides from Audentes Therapeutics's investor presentation, Sep 27, 2017

  1. Slide 1: Audentes Corporate Overview

    Audentes Corporate Overview September 27, 2017 Exhibit 99.4

  2. Slide 2: Safe Harbor

    Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Com

  3. Slide 3: Audentes Therapeutics

    Multi-product pipeline based on focused selection criteria Proven leadership team with significant experience Internal cGMP manufacturing provides core strategic advantage Targeting indications with limited or no treatment options Preliminary clinical data from lead programs expected end of 2017 Aud

  4. Slide 4: Experienced and Passionate Team

    Experienced and Passionate Team Audentes Therapeutics 117 employees based in the San Francisco Bay Area as of June 30, 2017 Matthew Patterson President and Chief Executive Officer Natalie Holles Senior VP and Chief Operating Officer Thomas Soloway Senior VP and Chief Financial Officer Suyash Prasad,

  5. Slide 5: Robust Pipeline

    Robust Pipeline AT132 AT342 AT307 AT982 Applying world-class AAV science to monogenic diseases with high potential for transformative clinical benefits IndicationStage of DevelopmentCommercial RightsProof-of-ConceptIND EnablingPhase 1/2XLMTMCrigler-Najjar SyndromePompe DiseaseCASQ2-CPVT

  6. Slide 6: Audentes Internal cGMP Manufacturing

    Audentes Internal cGMP Manufacturing Leadership Position in AAV Manufacturing Superior control over timelines, cost and IP Enables rapid addition of new programs 38,000 square feet in South San Francisco 2 x 500L scale ongoing to supply clinical trials In-house QC lab for critical release assays Add

  7. Slide 7: AT132 X-linked myotubular myopathy

    AT132 X-linked myotubular myopathy

  8. Slide 8: XLMTM: A Fatal Disease with no Treatment Options

    XLMTM A Fatal Disease with no Treatment Options Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males AAV8 effectively penetrates skeletal muscle Muscle tissue is otherwise reasonably healthy and exhibits no dystrophic

  9. Slide 9: A Single Treatment with AT132 Results in Dramatic Improvement & Survival in Mouse and Dog Models

    Normal (n=13) XLMTM (n=2) XLMTM+AT132 (n=3) 0 50 100 150 0 50 100 Percent survival Single injection of 2 x 1014 vg/kg AT132 in 3 week and 5 week old MTM1 KO mice M. K. Childers et al., Sci Transl Med, 2014; Buj-Bello, et al. Human Molecular Genetics, 2008; Note: vector dosing numbers have been adjus

  10. Slide 10: Treatment with AT132 Results in Dramatic Improvement and Survival in XLMTM Dogs

    *Dogs 3, 4 and 5, the three dogs treated in the proof-of-concept canine study, achieved a statistically significant improvement in survival. Treatment with AT132 Results in Dramatic Improvement and Survival in XLMTM Dogs

  11. Slide 11: AT132 Clinical Development Program

    AT132 Clinical Development Program INCEPTUS Prospective Natural History Run-in Study in XLMTM Patients N≈16 Longitudinal baseline and within-patient control for ASPIRO Facilitates enrollment in and operational aspects of ASPIRO ASPIRO A Phase 1/2 Gene Therapy Study in XLMTM Patients N=12 Assessment

  12. Slide 12: INCEPTUS: Key Findings

    INCEPTUS: Key Findings Prospectively collected natural history data confirm poor clinical outcomes of children living with XLMTM (n=18) Key Findings Data High frequency of life- threatening events 89 Adverse Events, 23 Serious Adverse Events, 1 patient death Approximately 100 cumulative hospitalizat

  13. Slide 13: CHOP-INTEND Scores

    CHOP-INTEND Scores All patients have severely impaired motor abilities and have missed all major gross motor milestones (rolling, standing, walking) Note: Interim data as of September 14, 2017 Age Range: 8 mos. to 4 yrs.

  14. Slide 14: MFM-20 Scores

    MFM-20 Scores All patients scoring well below normal on neuromuscular function Normal score in healthy children over 2 years of age Note: Interim data as of September 14, 2017 Age Range: 8 mos. to 4 yrs.

  15. Slide 15: Ventilator Dependence

    Ventilator Dependence Within the Previous 24 Hours Majority of patients require continuous (24/7) ventilator support Invasive Ventilation N=13/18 Non-Invasive Respiratory Support (Bi-PAP) N=5/18 Note: Interim data as of September 14, 2017

  16. Slide 16: Respiratory Sprinting Test – Median Time Off Ventilator

    Respiratory Sprinting Test – Median Time Off Ventilator Most patients cannot tolerate more than 10 min off ventilator Note: Only patients on invasive ventilator support undergo a sprinting test Note: Interim data as of September 14, 2017

  17. Slide 17: Maximum Inspiratory Pressures

    Maximum Inspiratory Pressures Respiratory strength of patients as measured by maximum inspiratory pressure is consistently well below normal levels Normal minimal pressures in healthy children Note: Interim data as of September 14, 2017

  18. Slide 18: ASPIRO Phase 1/2 Clinical Study

    ASPIRO Phase 1/2 Clinical Study Baseline AT132 Administration Subjects from INCEPTUS Weeks 1 – 4 Prednisolone Weeks 5–9 Taper Extension study Baseline Assessments Neuromuscular Respiratory Biopsy Assessments Neuromuscular Respiratory Biopsy Assessments Neuromuscular Respiratory Biopsy Assessments Ne

  19. Slide 19: AT342 Crigler-Najjar syndrome

    AT342 Crigler-Najjar syndrome

  20. Slide 20: Crigler-Najjar Syndrome: A Rare Disease that Leads to Neurological Damage and Death

    Crigler-Najjar Syndrome A Rare Disease that Leads to Neurological Damage and Death Significant bilirubin accumulation that can lead to irreversible neurological damage and death Current treatments: > 12 hours/day of phototherapy, liver transplant Estimated incidence of 1 in 1 million newborns AAV8 e

  21. Slide 21: AT342 Rapidly Reduces Bilirubin Levels in Crigler-Najjar Mouse Model

    AT342 Rapidly Reduces Bilirubin Levels in Crigler-Najjar Mouse Model A single tail vein injection of AT342 in a knockout mouse model rapidly reduced and normalized bilirubin levels for the duration of the study Previously published study with AAV8-UGT1A1 in a knockout mouse shows durable effect out

  22. Slide 22: AT342 Development Program

    AT342 Development Program LUSTRO Prospective Natural History Run-in Study in Crigler-Najjar Patients (N=16 to 18) Longitudinal baseline and within-patient control for VALENS Facilitates enrollment in and operational aspects of VALENS VALENS A Phase 1/2 Gene Therapy Study in Crigler-Najjar Patients N

  23. Slide 23: VALENS Phase 1/2 Clinical Study

    VALENS Phase 1/2 Clinical Study Open-Label, Ascending-Dose, Safety & Preliminary Efficacy Study Assessments Initial assessments Liver biopsy Weeks 5–9 Taper Weeks 13 – 17 Weaning Weeks 1 – 4 Prednisolone Assessments ∆ Bilirubin Weeks 1 – 12 Normal prescribed phototherapy dose Assessments Liver biops

  24. Slide 24: AT982 Pompe Disease

    AT982 POMPE DISEASE AUDENTES >> Courageous Patients. Bold Effort.

  25. Slide 25: Pompe Disease: A Rare, Severe, Progressive Neuromuscular Disease

    Pompe Disease A Rare, Severe, Progressive Neuromuscular Disease Severe muscle weakness, respiratory failure, and in infants, increased cardiac mass and heart failure Spectrum of disease from severe (infantile/early-onset) to more attenuated (juvenile/late-onset) Estimated incidence of 1 in 40K Effic

  26. Slide 26: AT982 Development Path to planned phase 1/2 clinical study

    AT982 Development Path to planned phase 1/2 clinical study Activity Overview and Achievements Preclinical studies Proof of concept established in murine model Comprehensive construct selection study ongoing - Muscle, neuronal and liver-directed vectors, AAV8 & AAV9 Functional, biochemical, immunolog

  27. Slide 27: AT307 Catecholaminergic polymorphic ventricular tachycardia (CPVT)

    AT307 Catecholaminergic polymorphic ventricular tachycardia (CPVT)

  28. Slide 28: CASQ2-CPVT: A Life-Threatening Inherited Arrhythmia

    CASQ2-CPVT A Life-Threatening Inherited Arrhythmia Ventricular arrhythmias and sudden death in response to stress and/or exercise Prevalence estimated at > 6,000 in addressable markets with mortality of 30-50% by age 30 AAV9 vector capsid effectively penetrates heart tissue Heart tissue is otherwise

  29. Slide 29: AT307 Prototype Prevents VT in Newborn Mice and Reverses VT in Adult Mice

    A single administration of an AT307 prototype achieved: Near normal levels of CASQ2 protein expression Reduction in pre-arrhythmic events and ventricular tachycardia to normal levels in both newborn and adult mice Denegri et al., Circulation, 2014 Newborn Mice P < 0.001 P < 0.001 P < 0.001 P < 0.001

  30. Slide 30: Financial Overview & Summary

    Financial Overview & Summary

  31. Slide 31: Financial Overview

    Jun. 30, 2017 cash, equivalents & short-term investments: $145M Funded to achieve key value inflection milestones: XLMTM: Interim results from the ASPIRO study Crigler-Najjar: Interim results from the planned VALENS study Pompe disease: File IND, initiate Phase 1/2 study for systemic administration

  32. Slide 32: Audentes Highlights

    Audentes Highlights Treating devastating diseases with high unmet medical need Potential for transformational disease impact Compelling Pipeline AAV Gene Therapy Leadership Team with significant rare disease and gene therapy expertise Robust internal research, analytical and large-scale cGMP manufac

  33. Slide 33: Audentes Corporate Overview

    Audentes Corporate Overview September 27, 2017

Audentes Therapeutics — Investor Presentation (September 2017) on 6ix